Companies › EVMN
EVOMMUNE INC (EVMN)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0002044725 · EDGAR filings · Updated 2026-07-16
EVOMMUNE INC (EVMN) has reported institutional ownership of 96.0%, with 84 institutional managers holding positions valued at $793.4M per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.
Latest updates
- 2026-07-16 — SCHEDULE 13G filed
- 2026-07-10 — Insider transaction reported (Form 4)
- 2026-07-08 — Insider transaction reported (Form 4)
- 2026-06-29 — Prospectus supplement (424B3) filed
- 2026-06-29 — Current report (8-K) filed
- 2026-06-24 — Insider transaction reported (Form 4)
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, EVOMMUNE INC has 84 institutional holders and institutional ownership of 96.0%.
Insider activity
Insiders reported 32 transactions (5 buys, 0 sells) across 13 reporting insiders, with a net reported value of $70.0M.
Data flags from SEC filings
Related companies
UROGEN PHARMA LTD (URGN) · JANUX THERAPEUTICS INC (JANX) · THERAVANCE BIOPHARMA INC (TBPH) · PHATHOM PHARMACEUTICALS INC (PHAT) · HARROW INC (HROW) · ARS PHARMACEUTICALS INC (SPRY)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-16.